The field has moved fast. Not long ago longevity was treated as a curiosity; now Longevity's a real investment category, on track to reach $67B by 2035. That shift is the thing worth paying attention to. The good companies aren't selling immortality. They're going after healthspan, treating aging as a root cause, and measuring themselves against clinical results.